VE-cadherin-CreERT2 transgenic mouse: A model for inducible recombination in the endothelium

Arnaud Monvoisin, Jackelyn A. Alva, Jennifer J. Hofmann, Ann C. Zovein, Timothy F Lane, M. Luisa Iruela-Arispe*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

186 Scopus citations


To introduce temporal control in genetic experiments targeting the endothelium, we established a mouse line expressing tamoxifen-inducible Cre-recombinase (Cre-ERT2) under the regulation of the vascular endothelial cadherin promoter (VECad). Specificity and efficiency of Cre activity was documented by crossing VECad-Cre-ERT2 with the ROSA26R reporter mouse, in which a floxed-stop cassette has been placed upstream of the β-galactosidase gene. We found that tamoxifen specifically induced widespread recombination in the endothelium of embryonic, neonatal, and adult tissues. Recombination was also documented in tumor-associated vascular beds and in postnatal angiogenesis assays. Furthermore, injection of tamoxifen in adult animals resulted in negligible excision (lower than 0.4%) in the hematopoietic lineage. The VECad-Cre-ERT2 mouse is likely to be a valuable tool to study the function of genes involved in vascular development, homeostasis, and in complex processes involving neoangiogenesis, such as tumor growth.

Original languageEnglish (US)
Pages (from-to)3413-3422
Number of pages10
JournalDevelopmental Dynamics
Issue number12
StatePublished - Dec 2006


  • Cadherin-5
  • Cre-recombinase
  • Endothelium
  • Tamoxifen
  • Transgenic mice
  • Tumor angiogenesis
  • VE-cadherin

ASJC Scopus subject areas

  • Developmental Biology


Dive into the research topics of 'VE-cadherin-CreERT2 transgenic mouse: A model for inducible recombination in the endothelium'. Together they form a unique fingerprint.

Cite this